
Loading, please wait...

Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates

Q1: What distinguishes the BIHS model from traditional hospital chains?
The BIHS model focuses on a continuum of care, prioritizing neighborhood clinics and home care to treat up to 80% of health needs outside the hospital environment.
Q2: How will physician performance be measured in this new system?
Physicians will not have revenue targets; instead, their performance will be based on clinical outcomes, patient experience, and the overall quality of care provided.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Bajaj Group invests ₹2,500 crore to launch an integrated healthcare network in India, focusing on clinics, home care, and multispecialty hospital services....
2 months ago

Recent studies reveal that Erdheim-Chester disease can manifest as glomeruloid haemangiomas driven by elevated VEGF-A levels. This discovery highlights a paracrine mechanism involving MAPK-activated histiocytes, providing new insights into the atypical cutaneous manifestations of this rare histiocytic neoplasm.
Today

A study confirms that short-course preoperative endocrine therapy significantly reduces Ki67 levels in ER-positive breast cancer, with the MammaPrint assay acting as a key predictor of this functional response.
Today

Researchers from IIT Bombay, IISER Pune, and IISER Kolkata have discovered a novel peptide, KTDP, that blocks the motor protein kinesin-1 to lower blood lipids by 50%. Crucially, this mechanism does not cause fat buildup in the liver, offering a safer preclinical pathway for metabolic and cardiovascular therapy.
Today

Researchers have developed a facile method to prepare bone-targeting polypeptide nanoparticles using aza-Michael addition in aqueous environments. These biodegradable SCNPs offer adjustable size and stimuli-responsiveness, making them a promising platform for targeted orthopedic drug delivery.
Today

Researchers have developed a modular PEG-based scaffold that simplifies the creation of multi-agonist peptide therapeutics. Using GLP-1 and amylin agonists as a model, this platform enables rapid, modular assembly of potent multi-receptor drugs, offering a new route for treating obesity and metabolic diseases.
Today